Uses of Creao

Creao drug with the brand name methylprednisolone, a corticosteroids, endocrine, anti-inflammatory drug, should be used in the treatment of a variety of diseases such as bronchial asthma, anaphylaxis, osteoarthritis, lupus erythematosus. However, the drug also causes a lot of side effects when used for a long time, so it is advisable to weigh the benefits - harms before using.

Creao drug with the brand name is methylprednisolone, belongs to the group of corticosteroids, endocrine drugs, and anti-inflammatory drugs. It has anti-inflammatory and immunosuppressive effects of glucocorticoids with typical diseases such as:
Asthma Anaphylaxis Acute laryngeal edema Acute laryngitis Post-surgery Osteoarthritis Synovitis in osteoarthritis Rheumatoid arthritis , including juvenile rheumatoid arthritis, acute and subacute bursitis, acute and nonspecific bursitis, acute gouty arthritis, psoriatic arthritis, ankylosing spondylitis, lupus erythematosus Severe lupus glomerulonephritis, glomerulonephritis edema Immunodeficiency syndrome (AIDS) Secondary cerebral edema due to primary or metastatic tumor and/or in combination with surgery or radiation therapy, tuberculous meningitis , exacerbation of sclerosis Motor and/or sensory deficits and reduced risk of paralysis in patients with acute spinal cord injury. Laryngitis in children

Creao injection 40mg is available as intramuscular, intravenous or intravenous infusion. The vial for injection is dissolved in sterile distilled water, if administered intravenously, it should be injected slowly over a period of at least 5 minutes. For intravenous infusion, the solution for injection should be diluted with 5% dextrose, or 0.9% sodium chloride prior to infusion.
Anaphylaxis: For adults, the initial dose is 30 mg/kg intravenously over 3-15 minutes, repeated every 4-6 hours. Then add a slow intravenous infusion of 30 mg/kg every 12 hours for 2-4 days. The high dose is maintained until the condition is stable, the duration of treatment should not exceed 48-72 hours. Acute Asthma: Adults 40-120 mg IV every 6 hours until asthma is controlled. Children dose 1-2 mg/kg/day, varies depending on disease status and responsiveness rather than age and weight, the lowest dose in children is 0.5 mg/kg/day. Rheumatic disorders unresponsive to standard therapy or exacerbations require treatment at a dose of 1 g/day for 1-4 days or 1 g/month continuously for 6 months, intravenously for at least 30 minutes. Systemic lupus erythematosus not responding to standard therapy or exacerbation requires treatment at a dose of 1 g/day for 3 days, given intravenously for at least 30 minutes. Edema (glomerulonephritis, lupus nephritis) unresponsive to standard therapy or exacerbation requiring treatment at 30 mg/kg every other day, for 4 days, or 1 g/day, for 3.5-7 days, intravenously for at least 30 minutes. Multiple sclerosis not responding to standard therapy or exacerbation requires treatment at 1 g/day for 3-5 days, intravenously for at least 30 minutes. Over 13 years of age with immunodeficiency syndrome (AIDS) requiring parenteral glucocorticoid therapy to support the treatment of Pneumocystis carinii infection with moderate to severe pneumonia should intravenous methylprednisolone 40 mg/time, every 6-12 hours up to 21 days or until the end of the course of treatment. Prevention of paralysis due to acute spinal cord injury: Within 3 hours of injury, an initial dose of 30 mg/kg IV over 15 minutes, 45 minutes rest, then 5.4 mg/kg/hour IV over 23 hours . Within 3-8 hours after injury, 30 mg/kg intravenously over 15 minutes, then 45 minutes rest, then 5.4 mg/kg/hour intravenously for 47 hours. Laryngitis in children: The initial intravenous dose is 1-2 mg/kg and the subsequent intravenous dose is 0.5 mg/kg every 6-8 hours.

Creao is contraindicated in cases of hypersensitivity to methylprednisolone, people with severe infections, septic shock and meningitis, fungal infections, viral, fungal or tuberculosis skin lesions, who are receiving live attenuated vaccines. force.

Adrenal insufficiency secondary to medication may persist for several months after drug discontinuation. The risk of this side effect can be minimized with gradual dose reduction. Creao medicine can cause immunosuppression, increase the risk of infection, different severity. However, the higher the Creao dose, the higher the risk of infection. Limiting contact with people with chickenpox or shingles because a weakened immune system during treatment with Creao can make it difficult to cure the disease and increase the risk of death. During the use of the drug, live vaccines should not be given, especially to people with a poor immune response, because it may reduce the effectiveness of the vaccine. Creao is indicated for people with latent or recurrent tuberculosis, which must be closely monitored because the disease is likely to recur. Prolonged use of Creao may increase the risk of osteoporosis and fractures. Moderate to high doses of Creao may cause hypertension, salt and water retention, and increased potassium excretion. Long-term use of Creao can cause cataracts, damage to the optic nerve and increase eye infections secondary to fungi or viruses. Long-term use of Creao can cause endocrine disorders such as Cushing's syndrome, amenorrhea or amenorrhea, changes in sperm count in men, decreased glucose tolerance, increased blood sugar production and the risk of diabetes. Disconnect the road . Use with caution in patients with heart failure and hypertension, as the drug can cause arrhythmias and/or pulse and/or cardiac arrest when given rapidly by intravenous injection at high doses. Systemic use of Creao may cause skin side effects including skin atrophy and thinning, acne, increased sweating, hirsutism, facial erythema, petechiae, hematoma, and skin pigmentation disorders. scars, calluses, skin atrophy and sterile abscesses, kaposi flesh tumors. On the digestive system, Creao can cause nausea, vomiting, anorexia leading to weight loss, appetite leading to weight gain, diarrhea, constipation, abdominal distention, pancreatitis, inflammation and ulceration of the esophagus, relapsing, barrel, bleeding, and slow healing of peptic ulcers. Headache, dizziness, insomnia, restlessness and hyperactivity, ischemic neuropathic pain, abnormal electroencephalogram (EEG) and seizures are side effects of Creao on the nervous system. Prolonged systemic use of Creao in pregnant women may result in low birth weight babies. Before use, it is necessary to consider carefully, because there are still many other possible risks to the mother and fetus. The drug is not contraindicated in nursing mothers.

For acute cases, short-term use, must consider how to use the lowest dose, in the shortest time and still achieve high treatment effect.
For long-term treatment, if adrenal suppression occurs, the dose should be reduced gradually, rather than abruptly stopping. Taking a single dose a day causes less side effects than dividing doses, taking every other day, every 2 days, in the morning will reduce adrenal suppression. Simultaneously, risk for bone, hematopoiesis, glucose tolerance, eye and blood pressure should be monitored and assessed.
When using high doses of Creao system, it is recommended to prevent peptic ulcers with H2-histamine receptor antagonists, calcium supplements to prevent osteoporosis. In addition, patients should also be warned about the possibility of infection during treatment.

Creao should not be used together with drugs metabolised by CYP3A4 (barbiturates. phenytoin. rifampin, ephedrine, carbamazepine) because glucocorticoids can inhibit the activity of CYP3A4 and conversely CYP3A4 can alter metabolism and release of glucocorticoids. Concomitant use of Creao with Cyclosporin is not recommended, as it reduces the concentration of methylprednisolone and increases the plasma concentration of cylosporin, and increases the risk of convulsions. Creao should not be used together with insulin and/or hypoglycemic agents as it may increase blood glucose levels. Creao should not be used with drugs containing estrogen, because it increases the concentration of transcortin, increasing the effect of hydrocortisone. Creao should not be used with an ulcerogenic drug such as indomethacin, as it may increase the risk of peptic ulcer. Concomitant use with aspirin should be used with caution in hypoprothrombinemic patients, as it may increase aspirin clearance, lead to decreased serum salicylates, or increase the risk of salicylate toxicity upon discontinuation of methylprednisolone. Creao should not be used together with hypokalemic drugs (thiazides, furosemide, ethacrylic acid) because of the possible increased risk of potassium loss. Creao should not be used together with a live attenuated vaccine, because it can inhibit the antibody response, causing inactivation of the live attenuated vaccine, thereby increasing the risk of disease spread. Creao should not be used together with oral anticoagulants, because it may increase or decrease the effect of the drug when used with corticosteroids. Creao drug with the brand name methylprednisolone, a corticosteroid, endocrine, anti-inflammatory drug, should be used in the treatment of a variety of diseases such as bronchial asthma, anaphylaxis, osteoarthritis, lupus erythematosus. To ensure effective use and avoid unwanted side effects, patients need to use the drug exactly as directed by the doctor, professional pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.